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Patients with drug-naive bipolar disorder in remission after 8 weeks of treatment
had decreased serum uric acid concentrations
Abstract
Background: Evidence indicates that the serum concentration of uric acid (UA) in patients may relate both
to the pathophysiology and therapeutics of bipolar disorder (BPD). The purpose of this study was to
examine the changes and clinical significance of serum UA concentrations in first-episode manic patients
suffering from BPD. Methods: Seventy-six drug-naive patients with first-episode bipolar mania and 76 ageand gender-matched healthy subjects were recruited. Young Mania Rating Scale and Hamilton Depression
Rating Scale were used to assess clinical symptoms. We tested serum UA concentrations by sandwich
enzyme-linked immunosorbent assay at baseline and at the end of 8-week treatment in BPD patients and
in the control group. Results: After 8-week quetiapine and sodium valproate treatment, this study revealed
that the serum UA concentrations in remitted patients were significantly lower than nonremitted patients;
however, those remitted patients still had higher serum UA than healthy controls. We discovered that the
baseline UA concentration was higher in nonremitted than remitted patients after 8 weeks of treatment.
Finally, a positive association was found between serum UA and symptom relief in the first episode of
manic disorder patients. Conclusion: Patients with first-episode BPD had high levels of serum UA, which
responds to treatment mainly in remitted patients. Our results suggest that serum UA concentrations
might present potentially a trait marker in bipolar patients.
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Background: Evidence indicates that the serum concentration of uric acid (UA) in patients
may relate both to the pathophysiology and therapeutics of bipolar disorder (BPD). The
purpose of this study was to examine the changes and clinical significance of serum UA
concentrations in first-episode manic patients suffering from BPD.
Methods: Seventy-six drug-naive patients with first-episode bipolar mania and 76 ageand gender-matched healthy subjects were recruited. Young Mania Rating Scale and
Hamilton Depression Rating Scale were used to assess clinical symptoms. We tested
serum UA concentrations by sandwich enzyme-linked immunosorbent assay at baseline
and at the end of 8-week treatment in BPD patients and in the control group.
Results: After 8-week quetiapine and sodium valproate treatment, this study revealed that
the serum UA concentrations in remitted patients were significantly lower than nonremitted
patients; however, those remitted patients still had higher serum UA than healthy controls.
We discovered that the baseline UA concentration was higher in nonremitted than remitted
patients after 8 weeks of treatment. Finally, a positive association was found between
serum UA and symptom relief in the first episode of manic disorder patients.
Conclusion: Patients with first-episode BPD had high levels of serum UA, which
responds to treatment mainly in remitted patients. Our results suggest that serum UA
concentrations might present potentially a trait marker in bipolar patients.
Keywords: bipolar disorder, hyperuricemia, mania, therapeutic efficacy, uric acid

INTRODUCTION
Bipolar disorder (BPD) is a severe and chronic mental disorder with a lifetime prevalence of
approximately 1% to 2% in the general population (1). The disease is associated with a potentially
devastating impact on individual well-being including social, occupational, and general functioning
(2–4). Drugs such as mood stabilizers, atypical antipsychotics, and nondrug therapy, including
Abbreviations: BMI, body mass index; BP, blood pressure; BPD, bipolar disorder; CI, confidence interval; DSM-IV, Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition; FBG, fasting blood glucose; HDL-C, high density lipoprotein
cholesterol; OR, odds ratio; SPSS, Statistical Package for the Social Sciences; UA, uric acid.
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electroconvulsive therapy, transcranial magnetic stimulation, and
psychotherapy, are shown to have limited efficacy; the outcomes
in a large number of patients are unsatisfactory (5–7). Therefore,
the therapeutics of BPD remains an important challenge in
psychiatry. This may be due to the underlying neurobiology of
the diseases being still largely unclear. Improved understanding
of the pathophysiological basis of BPD is required for the
development of more targeted therapeutics.
Uric acid (UA) and purine regulate a number of brain
activities such as cognition, memory, and mood and highly
exist in the limbic regions and basal ganglia of brain (8). These
brain regions have been reported to have some abnormalities in
BPD through neuroimaging studies (9, 10). Growing evidence
from genetic and clinical studies suggested the purinergic
system might be a contributing factor in the pathophysiology
of BPD (8). The purinergic system includes signaling
pathways of the neurotransmitter adenosine triphosphate and
the neuromodulator adenosine. Agonists of adenosine are
considered to have sedative, anticonvulsant, antiaggressive, and
antipsychotic properties, whereas its antagonists, for example,
caffeine, may cause irritability and disrupt the sleep–wake
cycle, which is a common precipitant for manic relapse (11).
In addition, adenosinergic dysfunction is found in euthymic
patients with BPD, and there is a significant association between
higher functioning impairment and lower concentrations of
adenosine in blood (12).
UA is a purine metabolite produced by the xanthine
oxidoreductase from xanthine or hypoxanthine. Peripheral
and central UA concentrations are highly correlated (13).
An increased serum UA concentration could be due to the
result of amplified purinergic turnover or reduced adenosine
transmission (14, 15). Over the past decades, several studies
have shown that BPD patients in all phases (manic/hypomanic,
mixed depressed, or euthymic) could have an increased serum
UA concentration, as compared with healthy or other mental
disorder subjects (16–20). These studies have indicated altered
regulation of purinergic system in BPD (21). However, no
significant differences in serum UA levels were also reported
between euthymic BPD and healthy subjects (12, 20, 22, 23).
Also, no significant differences were found in serum UA between
the patients with manic episodes and euthymic status (20, 24,
25). Therefore, whether an elevated UA concentration might be
a trait marker for BPD remains to be determined.
A positive correlation was reported between serum UA levels
and symptom severity in mania patients (18, 19, 26). In line with
their study, a combinational therapy of valproate together with
allopurinol (hyperuricemia-lowering drug) results in significant
improvements in patients suffering from acute mania (27, 28). In
contrast, no improvement was also reported by using allopurinol
in treating manic symptoms (29, 30). Also, similar UA levels
between manic state and remitted state were reported (20, 24).
In consideration of controversial data from literature, we
carried out a cohort study on first-episode and drug-naive manic
patients and investigated whether (1) serum UA concentrations
differ among manic episode, remission after treatment, and
healthy subjects, matched for age and gender; (2) treatment with
an atypical antipsychotic drug (quetiapine) and mood stabilizer
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(sodium valproate) affects the serum UA concentrations in
manic patients; and (3) there is any relationship between serum
UA concentration and the therapeutic efficacy.

METHODS
Subjects
Seventy-six inpatients were recruited from inpatients suffering
BPD. The study was conducted from January 2015 to December
2017 in Beijing Hui-Long-Guan Hospital, affiliated with Clinical
Medical College of Peking University, China. The inclusion
criteria were subjects between 18 and 45 years old, diagnosis of a
manic/hypomanic episode by the consensus of two independent
senior psychiatrists according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition criteria (31), and
first-episode and never-treated history, which was confirmed by
collateral histories from family members. All subjects were Han
Chinese. The patients with a history of affective disorder and
other Axis I diagnoses such as schizophrenia and neurological
illness were excluded from this study.
The control group had 76 healthy subjects and was recruited
from the local community, matched with the patients for age
and gender. Healthy subjects were 18 to 45 years of age without
any record of personal or family history of psychiatric disorders
and were Han Chinese. All participants were without any
record of organic brain diseases, cardiovascular disease, chronic
inflammatory disease, diabetes, nephropathy, and gout or other
diseases associated with changes in serum UA concentrations, as
determined by a complete medical history, physical examination,
and laboratory tests. Neither bipolar patients nor control subjects
were taking drugs or medications, none had alcohol abuse/
dependence, and none were pregnant/breastfeeding, which
could influence UA concentrations.
All subjects gave signed and informed consent that was
approved by the institutional review board of the Beijing HuiLong-Guan Hospital, Peking University.
All patients received the combination quetiapine (606.58 ±
150.85 mg, daily) plus sodium valproate (1,077.97 ± 338.77 mg,
daily) treatment for 8 weeks, which was in agreement with the
first-line treatment of mania in international evidence-based
guidelines (32).

Assessment
Psychopathological symptoms of patients were assessed on the
day of blood sampling by four psychiatrists who were blind to
the clinical status and treatment conditions. Young Mania Rating
Scale (YMRS) (33) was used to measure the severity of manic
symptoms before and after treatment. YMRS and the 17-item
version of the Hamilton Depression Rating Scale (HDRS) (34)
were used to confirm the remission during the recovery period.
The patients in remission were defined by both YMRS and HDRS
scores being ≤7. To ensure consistency and reliability of ratings,
before undertaking the study, four psychiatrists who worked over
5 years in clinical practice simultaneously received a training
session on how to use YMRS and HDRS, ensuring a correlation
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RESULTS

coefficient maintained greater than 0.8 by repeated assessments
across the study.
The blood samples from all subjects were taken between 6 and
7 after overnight fasting as baseline and were taken again after 8
weeks of treatment between 6 and 7. Serum UA concentrations
were assessed using sandwich enzyme-linked immunosorbent
assay, which was by a commercially available kit (DRG kit cat. no.
EIA-2925, Germany). The parameters potentially affecting serum
UA concentrations such as metabolic parameters (triglycerides,
high-density lipoprotein cholesterol, and fasting blood glucose)
and kidney function (creatinine, urea) were also measured. The
height, body weight, and blood pressure of all subjects were
measured. Body mass index (BMI) was calculated as body weight
in kilograms divided by height in meters squared. Hyperuricemia
was defined as serum level of UA >420 µmol/l (7.0 mg/dl) for men
and >360 µmol/l (6.0 mg/dl) for women (17). Current smoking
referred to smoking at least one cigarette per day over the last 1
month before enrollment.

Demographic and clinical characteristics of the study population
are shown in Table 1. Patients and controls were matched with
respect to age and gender. There were no significant differences
in demographic and clinical characteristics (Table 1). Sixtyeight cases were mania (39 men and 29 women), and the other
eight cases were hypomania (five men and three women).
No differences in the levels of serum UA between mania and
hypomania patients (379.74 ± 99.25 vs 368.50 ± 103.70 µmol/l,
t = 0.34, p = 0.74).
After 8 weeks of quetiapine and sodium valproate treatment,
YMRS scores (t = 25.76 p < 0.01) and serum UA concentrations
(t = 3.36, p = 0.01) were lower compared to baselines (Table 2,
Figure 1). Fifty-three patients reached remission status according
to the scores of YMRS and HDRS. We detected that the serum UA
concentrations were significantly lower in the remission group
compared to nonremission group both at baseline (361.89 ±
92.36 vs 416.96 ± 105.31 µmol/l, t = 2.29, p = 0.03) and after 8
weeks of treatment (323.57 ± 73.53 vs 364.57 ± 91.98 µmol/l,
t = 2.07, p = 0.04) (Figure 2). These differences remained after
controlling for age, gender, and BMI (all p < 0.05).
Pearson correlation analysis showed that serum UA
concentrations were not correlated with severity of symptoms,
which were assessed by YMRS at both baseline (r = 0.18, p =
0.12) and at the end of 8 weeks of treatment (r = 0.21, p = 0.07).
However, there was a significant correlation between changes in
serum UA concentrations and that of the change of the YMRS
scores after treatments (pretreatment − posttreatment, r = 0.25,
p = 0.03; Figure 3). The correlations remained significant after
controlling for the baseline YMRS score and UA levels (r = 0.23,
p = 0.047).
The prevalence rate of hyperuricemia between the remitted
patients and healthy controls did not differ (17.0% and 10.5%,
χ2 = 1.14, p = 0.29). The prevalence rate of hyperuricemia in all
patients at baseline was 40.9%, which was significantly higher
than the remitted patients and healthy controls (χ2 = 18.25, p <
0.01; and χ2 = 8.27, p < 0.01, respectively). A paired-sample t test

Statistical Analysis
The differences of demographic data between patients and
controls were analyzed by χ2 test or independent-samples t test,
wherever it is appropriate. The paired t test was used to compare
serum UA concentrations, YMRS scores, and HDRS scores
between the baseline and posttreatment in the patient group.
The paired t test was also used to compare serum UA levels
in drug-naive manic patients and patients in remission after
treatments. Pearson correlation coefficient was used to evaluate
the relationship between serum UA levels and YMRS scores
when data were in normal distribution. Independent-samples
t test was applied to single-time-point data. When significant
differences were detected, covariant analysis controlling for
BMI, age, and sex and Bonferroni post hoc analyses for multiple
comparisons were applied. Results are expressed as mean ± SD.
All statistical tests were two-tailed, and p < 0.05 was considered
as statistically significant. Statistical analyses were performed
using SPSS (version 17.0).

TABLE 1 | Demographic and clinical characteristics of drug-naive patients with first-episode manic patients and healthy controls.
Variable
Age (y)
Gender, male, n (%)
Education (y)
Marital status, married, n (%)
Duration of illness (d)
Current smoking, n (%)
BMI kg/m2
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
HDL-C (mmol/l)
TG (mmol/l)
FBG (mmol/l)
Urea (mmol/l)
Creatinine (µmol/l)
UA (µmol/l)

Manic patients (n = 76)

Healthy controls (n = 76)

χ2/t

p

26.34 ± 8.16
43 (56.6)
12.14 ± 3.33
32 (42.1)
37.26 ± 52.43
16 (21.1%)
22.14 ± 2.54
109.34 ± 11.98
73.22 ± 7.99
1.32 ± 0.36
1.24 ± 0.87
4.71 ± 0.67
4.56 ± 1.31
74.62 ± 18.61
378.55 ± 99.08

26.95 ± 6.67
43 (56.6)
12.74 ± 3.40
28 (36.8)
—
9 (11.8%)
21.97 ± 2.38
107.83 ± 9.77
73.16 ± 8.24
1.33 ± 0.46
1.28 ± 0.65
4.68 ± 0.58
4.24 ± 0.96
70.04 ± 15.86
293.39 ± 71.40

0.45
0.00
1.08
0.44

0.65
1.00
0.28
0.51

2.35
0.44
0.85
0.05
0.08
0.33
0.30
1.76
1.63
6.22

0.13
0.66
0.40
0.96
0.94
0.74
0.76
0.08
0.11
< 0.01

BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; FBG, fasting blood glucose levels.

Frontiers in Psychiatry | www.frontiersin.org

3

October 2019 | Volume 10 | Article 767

Chen et al.

Drug-Naive BPD in Remission

TABLE 2 | Serum UA levels, YMRS scores, and HDRS scores among bipolar
patients receiving treatment for 8 weeks.
Variable
UA (µmol/l)
YMRS scores
HDRS scores

Baseline

Week 8

t

p

378.55 ± 99.08
27.47 ± 5.23
3.11 ± 3.04

335.97 ± 81.18
6.44 ± 5.73
4.01 ± 4.14

3.361
25.76
−1.615

0.01
<0.01
0.11

nonremitted patients, although they were still had higher than
healthy controls. Furthermore, we showed that the baseline UA
was significantly higher in nonremitted than remitted patients
after 8 weeks of treatment. Also, a positive association was found
between serum UA and symptom relief in these patients.
In the past few years, a number of studies have investigated
the changes of UA in patients suffering BPDs; however, the data
are inconsistent and even controversial (20, 22, 35, 36). This
may be due to various confounders involved in studies because
the nature of BPD is a complex, chronic, and heterogeneous
psychiatric disease (37). Two studies have investigated serum
UA levels in first-episode manic patients with the sample sizes
of 20 based on the criteria of Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition and 31 based on the criteria
of International Classification of Diseases, 10th Revision (26, 38).
Both studies have had relatively small sample size without taking
into consideration of confounders such as the levels of creatinine,
cholesterol, and glucose and BMI, which could have influenced
UA levels (39, 40). We conducted a prospective study on a cohort
of 68 first-episode manic patients controlling for potential
confounders including metabolic and kidney function–related
variables. From this study, we suggest that a possible contributing
factor could be due to discrepancy of baseline levels of UA in the
BPD patient cohort studied.
Overall, recent studies support that the patients suffering
BPD at manic phase have significantly higher levels of serum UA
during both acute and chronic phases compared with healthy
controls (24, 28, 38, 41). Also, the serum UA levels were higher in
mania phase than depression and remission phases in the same
patients suffering from BPD (19, 25, 42). Consistent with these
results, our study showed that first-episode drug-naive patients
in manic phase had significantly higher serum UA than those of
patients in remission and healthy controls. Therefore, we support
that increased UA levels were associated with a state of manic
episode, which may be used as a routine check in the manic
phase of BPD (13).
Psychotropic and antipsychotic drugs could have different
effects on serum UA levels. Lithium and carbamazepine reduce
UA serum levels (43, 44). Zotepine reduces UA levels more
than risperidone and haloperidol (45, 46). Conversely, it has
been reported that olanzapine increases UA levels in moderate
mania (47, 48). The present study observed that bipolar patients
in mania phase treated with quetiapine and valproate decreased
serum UA, which was in consistence with a report of a previous
study (18). Previous study showed that adjunctive allopurinol
reduces UA and increases remission rate in manic patients
(49). Similarly, we found that decreased UA was in parallel
with an improvement of YMRS scores in mania patients. It was
possible that UA may have contributed to the severity of mania
symptoms, while reduced UA helped relief of manic symptoms.
One explainable mechanism was that alleviated oxidative stress
by lowering UA may have led to the effect of antimanic drug
because an elevated UA is known to induce oxidative stress,
which may worsen the pathophysiology of manic disorder
(50–53).
The present study was the first to investigate the serum UA
levels in patients suffering from the first manic episode who

UA, uric acid; YMRS, Young Mania Rating Scale; HDRS, Hamilton Depression
Rating Scale.

FIGURE 1 | Serum UA concentarion from baseline over 8 weeks of treatment.
*p < 0.05.

revealed that serum UA levels of the remitted patients were
significantly higher than these patients in drug-naive phase
(Tables 1 and 2, t = 2.71, p < 0.01). Independent-samples t test
showed that serum UA levels in healthy controls were lower than
first-episode drug-naive patients (Table 1, t = 6.22, p < 0.01)
and the remitted patients after 8-week treatments (t = 2.49, p =
0.01; Figure 4). Covariance analysis showed that the serum UA
differences between healthy controls and manic patients and
remitted patients remained statistically significant after adjusting
for gender, age, and BMI (all p < 0.01; Table 1 and Figure 4).

DISCUSSION
This study analyzed the relationship of system levels of UA to
measures of YMRS and HDRS in first-episode manic patients
suffering from BPD prior and after 8-week quetiapine and
sodium valproate treatment. Our results revealed that the serum
UA levels in remitted patients were significantly lower than
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FIGURE 2 | Serum UA levels R-BP (n = 53) and NR-BP (n = 23) at baseline (left panel) and after treatment (right panel). R-BP, remitted bipolar patients; NR-BP, nonremitted bipolar patients. *p < 0.05.

number of affected mood episodes, and longer mood stabilizer
exposure (12, 20, 22, 23).
The present study had several limitations. First, our data should
be seen as a pilot study instead of generalized clinical evidence
or relevance because our study had relatively small sample size,
especially of female patients from one district of China. Second,
bipolar patients with depressive episodes or recurrent episodes
(possibly with years of pharmacological intervention) were not
enrolled in this study. Third, the prevalence of cigarette smoking
was normally higher in patients with BPD than healthy controls,
but how smoking affects serum UA in BPD patients is still largely
unknown (55, 56). Fourth, all inpatients had the same dietary
profile; however, healthy subjects might have a different dietary
profile, which could affect the comparison of serum UA between
patients and healthy controls (57). Lastly, only one time point in
remission was checked; thus, the time course of UA response to
therapy remains unknown.

FIGURE 3 | Correlation between changes in serum UA levels and that in
YMRS scors after treatment (r = 0.25, p = 0.03).

CONCLUSIONS

have achieved remission after 8 weeks of treatment. We found
that serum UA levels in remitted patients were higher than those
in healthy controls after adjusting for age, gender, and BMI,
which supported the idea that altered purinergic regulation may
be involved in the genesis of BPD (19, 21, 24, 54). In addition,
several studies have reported higher levels of UA in the depressive
episodes of BPD compared with healthy controls (19, 24, 54).
Therefore, an increased UA may be a predisposition in bipolar
patients as a trait marker, which is independent of some current
or past affective episodes. On the other hand, it was noted that
some euthymic patents had similar UA levels as healthy controls
particularly if the patients had a longer duration of illness, high

Frontiers in Psychiatry | www.frontiersin.org

Bipolar patients at the first-episode drug-naive phase had
significantly higher levels of serum UA. Patients in remission after
8 weeks of treatment had significantly reduced serum UA, while
it was still higher than healthy controls. Patients in nonremission
after 8 weeks of treatment had significantly less reduction in
serum UA compared with those of remitted patients. Therefore,
high levels of serum UA were a pathological condition of bipolar
disease at manic phase, contributed to the severity of symptoms,
and were reduced in remitted patients, but not in nonremitted
patients. Furthermore, serum UA levels might be potentially a
trait marker in bipolar patients.
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